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On-demand use of rabeprazole for the management of sympto-
matic GERD incurs the least cost in comparison to the other 
PPIs evaluated. Utility gains were comparable for all on-demand
PPIs.
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OBJECTIVES: To asses the cost-effectiveness of two initial man-
agement strategies for the general practitioner in dyspepsia. The
two strategies investigated are prompt endoscopy and a Heli-
cobacter pylori test-and-treat strategy. METHODS: Pharma-
coeconomic data was gathered alongside the SENSE (Strategy:
Endoscopy versus Serology)-study from 1998 up to 2001.
Patients were randomized in the endoscopy (n = 105) and test-
and-treat (n = 118) group. The costs were standardized costs for
1999. Quality of life was measured at inclusion and one year
later, using the validated Dutch translation of the RAND-36
questionnaire. The results obtained were transformed into one
overall score, in terms of Quality Adjusted Life Years (QALYs).
An incremental cost-effectiveness ratio (ICER) was calculated as
incremental cost of test-and-treat over early endoscopy per
QALY gained. For estimating the uncertainty we calculated 95%
uncertainty limits using parametric bootstrap with angular trans-
formation. RESULTS: For the test-and-treat group the total costs
per patient were 511.02€ and the number of QALYs gained was
0.074 per patient. For the endoscopy group this was 748.08€
and 0.064 QALYs gained. The point estimate of the ICER indi-
cated cost-savings and QALYs gained. Parametric bootstrap
uncertainty limits indicate cost-savings per QALY gained
(75.7%) and cost savings per QALY lost ranging from 11,970€
to inﬁnity. CONCLUSIONS: According to our data, the Heli-
cobacter test-and-treat strategy is more cost-effective than
prompt endoscopy in the initial management of dyspepsia in
general practice.
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OBJECTIVES: To compare the cost-effectiveness of esomepra-
zole versus pantoprazole and generic omeprazole from the per-
spective of the statutory health insurance using a decision model
reﬂecting naturalistic treatment behaviour in GERD patients in
Germany. METHODS: The model applies to patients with endo-
scopically veriﬁed GERD receiving PPI therapy and covers a
period of 8 weeks. Therapies included were esomeprazole 20 and
40mg, omeprazole 20 and 40mg and pantoprazole 40mg. Real-
life treatment patterns and resource utilization for acute and
maintenance treatment were derived from 30 physician inter-
views, whereas healing rates after 4 and 8 weeks of treatment
were derived from published literature. Resource utilization
included visits, examinations and laboratory tests at primary
care physicians and specialists, drug treatment of GERD, hospi-
talizations and working incapacity. RESULTS: Total costs per
patient ranged between 137€ for esomeprazole and 202€ for
pantoprazole with total healing rates after eight weeks between
85% (omeprazole) and 96% (esomeprazole). No hospitaliza-
tions were observed and the few sick leaves reported were shorter
than 42 days, inducing no costs from the insurance perspective.
Costs per patient healed varied between 145€ (esomeprazole)
and 218€ (pantoprazole), with most of the treatments ranging
closely around 200€. Due to the relatively small sample size, we
tested the robustness of the results by conducting sensitivity
analyses representing different degrees of standardization in
input parameters. Cost-effectiveness did not differ much in either
scenario; standardizing e.g. physician costs and treatment dura-
tion resulted in costs per patient healed between 163€ (esomepra-
zole) and 210€ (omeprazole). CONCLUSIONS: The results
indicate that esomeprazole is a cost-effective treatment option
for patients with endoscopically veriﬁed GERD treated over 8
weeks. Strongest competitor for esomeprazole is treatment with
generic omeprazole. The current model will be extended to a 6
month period as soon as the data from a currently completed
study will become available.
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OBJECTIVES: To analyze the cost-effectiveness of capsule
endoscopy (CE) in diagnosing obscure gastrointestinal bleeding
(OGIB) from a health care payer perspective in France, the UK,
and Switzerland. METHODS: Based on clinical trial data, a
microsimulation model incorporating ﬁrst- and second-order
Monte Carlo simulation was developed. The model calculates
the costs per correctly diagnosed case in patients with OGIB.
Sensitivity and speciﬁcity for CE and the comparator push
enteroscopy (PE) as well as kind and number of other procedures
performed prior to diagnosis were evaluated from 7 controlled
clinical trials (n = 184). Procedure cost, cost of diagnostic failure
(false positive/negative diagnosis) were considered and incre-
mental cost-effectiveness ratios dependent on disease prevalence
are given. Cost data were estimated from a healthcare payer per-
spective using the “Assurance Maladie” (France), NHS Refer-
ence Cost (UK), and the TARMED (Switzerland). RESULTS:
Sensitivity for CE was 89–99% and 27–60% for PE. Speciﬁcity
values were 90–99% for CE and 50–70% for PE. In all 5 coun-
tries, CE was cost saving when the prevalence of the disease was
10% or higher. Most common use for CE is at a prevalence of
50%. Cost savings at a prevalence of 50% are 1508€ (France),
1695€ (UK) and 2240€ (Switzerland). Probabilistic sensitivity
analyses approved a high robustness for these results. CON-
CLUSIONS: CE proved to have a higher effectiveness than PE
when diagnosing obscure bleeding. Though procedure costs vary
substantially from country to country, incremental analysis
shows that the use of CE has a cost-saving potential in all three
countries.
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OBJECTIVES: Assessing the potential increase in GERD medical
treatment expenses and the impact of on-demand treatment with
